Navega Therapeutics Patents

Patent portfolio assigned to Navega Therapeutics (verified via public assignee records). Estimated patent count: 3. San Diego gene-therapy company (UCSD spinout) developing epigenetic (zinc-finger/CRISPR) NaV1.7 repression for chronic pain; lead program NT-Z001. Partner: Charles River Laboratories (CDMO / AAV9 manufacturing collaboration, gene-therapy accelerator program). Google Patents / EP publication EP4284927 lists 'Navega Therapeutics, Inc.' as applicant (epigenetic gene regulation for neurological disease and pain), so has_patents=true; patent_count_estimate=3 per aggregator (PatSnap Synapse) - approximate. Note: an earlier foundational NaV1.7 epigenetic-repression patent (WO2020210542) likely belongs to UC Regents, not Navega.